B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+4.4%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$28.4M
Cap. Flow
-$1.31B
Cap. Flow %
-42.81%
Top 10 Hldgs %
37.02%
Holding
95
New
15
Increased
19
Reduced
16
Closed
14
Avg Time Held
0.4 years
Top 10 Avg Time Held
0.4 years
Top 20 Avg Time Held
0.3 years

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$50.1M
2
BSX icon
Boston Scientific
BSX
+$37.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$30.9M
4
MRVI icon
Maravai LifeSciences
MRVI
+$24.4M
5
AXNX icon
Axonics, Inc. Common Stock
AXNX
+$21.7M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$90.4M
2
GKOS icon
Glaukos
GKOS
+$43.8M
3
AMGN icon
Amgen
AMGN
+$39M
4
ISRG icon
Intuitive Surgical
ISRG
+$30M
5
BLU
BELLUS Health Inc.
BLU
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 54.2%
2 Miscellaneous 45.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
26
Harrow
HROW
$1.03B
$27.7M 0.9%
1,452,538
– –
2023 Q1
1 quarter
ALEC icon
27
Alector
ALEC
$203M
$24.8M 0.81%
4,131,315
+925,000
+29% +$6.46M
2022 Q4
2 quarters
ANAB icon
28
AnaptysBio
ANAB
$1.4B
$23.5M 0.77%
1,154,423
+181,350
+19% +$3.68M
2022 Q4
2 quarters
DBVT icon
29
DBV Technologies S.A. American Depositary Shares
DBVT
$562M
$23M 0.75%
1,210,779
– –
2022 Q4
2 quarters
PEN icon
30
Penumbra
PEN
$12.6B
$22.7M 0.74%
65,844
-41,200
-38% -$12.7M
2022 Q4
2 quarters
MRVI icon
31
Maravai LifeSciences
MRVI
$973M
$22.4M 0.73%
+1,804,700
New +$24.4M
2023 Q2
0 quarters
ENTA icon
32
Enanta Pharmaceuticals
ENTA
$331M
$22.2M 0.73%
1,038,310
– –
2022 Q4
2 quarters
HLVX icon
33
DELISTED
HilleVax
HLVX
$21.5M 0.7%
1,249,246
-370,970
-23% -$5.75M
2022 Q4
2 quarters
CGEM icon
34
Cullinan Oncology
CGEM
$877M
$20.5M 0.67%
+1,908,865
New +$20.3M
2023 Q2
0 quarters
BCRX icon
35
BioCryst Pharmaceuticals
BCRX
$2.05B
$19.7M 0.64%
2,791,880
+846,746
+44% +$6.79M
2023 Q1
1 quarter
CMPX icon
36
Compass Therapeutics
CMPX
$151M
$18.9M 0.62%
5,954,273
+2,706,426
+83% +$8.5M
2022 Q4
2 quarters
RAPT icon
37
DELISTED
RAPT Therapeutics
RAPT
$18.4M 0.6%
+123,050
New +$19.2M
2023 Q2
0 quarters
VIR icon
38
Vir Biotechnology
VIR
$1.78B
$17.9M 0.58%
728,549
+124,513
+21% +$3.13M
2023 Q1
1 quarter
TERN icon
39
DELISTED
Terns Pharmaceuticals
TERN
$16.1M 0.53%
1,842,352
-154,703
-8% -$1.8M
2023 Q1
1 quarter
DYN icon
40
Dyne Therapeutics
DYN
$2.8B
$15.5M 0.51%
1,377,872
– –
2022 Q4
2 quarters
TMO icon
41
Thermo Fisher Scientific
TMO
$249B
$14.2M 0.47%
+27,300
New +$14.7M
2023 Q2
0 quarters
RYTM icon
42
Rhythm Pharmaceuticals
RYTM
$6.05B
$13.9M 0.45%
+843,087
New +$15.2M
2023 Q2
0 quarters
DHR icon
43
Danaher
DHR
$158B
$13.3M 0.43%
+62,491
New +$13.2M
2023 Q2
0 quarters
LUNG icon
44
Pulmonx
LUNG
$76.4M
$13.1M 0.43%
999,362
-163,932
-14% -$2.01M
2022 Q4
2 quarters
RGEN icon
45
Repligen
RGEN
$11.4B
$13M 0.43%
+92,000
New +$14.8M
2023 Q2
0 quarters
CRNX icon
46
DELISTED
Crinetics Pharmaceuticals
CRNX
$11.7M 0.38%
650,312
-1,369,402
-68% -$27.3M
2022 Q4
2 quarters
REPL icon
47
Replimune Group
REPL
$1.12B
$11.3M 0.37%
487,520
+413,855
+562% +$8.09M
2022 Q4
2 quarters
SLRN icon
48
DELISTED
ACELYRIN
SLRN
$10.4M 0.34%
+500,000
New +$10.2M
2023 Q2
0 quarters
GH icon
49
Guardant Health
GH
$21.8B
$9.67M 0.32%
+270,000
New +$7.75M
2023 Q2
0 quarters
ALXO icon
50
ALX Oncology
ALXO
$128M
$9.39M 0.31%
1,249,900
– –
2022 Q4
2 quarters
1
2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2023 Portfolio in Review

As of Q2 2023, Braidwell held 95 positions worth $3.06B, up 0.94% from $3.03B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $1.31B in Q2 2023, closing 14 positions and reducing 16 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $90.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 54% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Keros Therapeutics worth $46M.

  • Braidwell's largest Q2 2023 buy was Keros Therapeutics: 1,143,865 shares worth $46M.
  • Braidwell added most to Axonics, Inc. Common Stock in Q2 2023, an estimated $21.7M increase.
  • Braidwell's biggest Q2 2023 reduction was Glaukos, cutting an estimated $43.8M.
  • Braidwell fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $90.4M.
  • Braidwell's ten largest holdings make up 37% of its $3.06B portfolio in Q2 2023.
  • Braidwell opened 15 new positions and closed 14 in Q2 2023.
  • Braidwell's portfolio value rose 0.94% quarter-over-quarter to $3.06B.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.